Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Weaving, Gary Ronald (2010)
Languages: English
Types: Doctoral thesis
Subjects: QD, QH301, QM
Homocysteine is an amino acid formed by the metabolism of methionine. Increased plasma homocysteine concentrations are associated with cardiovascular disease, and it has been suggested that homocysteine lowering therapy may reduce cardiovascular risk. Plasma homocysteine measurements are frequently requested by clinicians investigating patients with vascular disease. A mechanism for homocysteine causing vascular disease has not yet been proven, but one possibility is that an elevated plasma homocysteine concentration may lead to the accumulation of asymmetric dimethylarginine (ADMA), a naturally occurring amino acid that inhibits nitric oxide synthase, resulting in impaired nitric oxide production, and therefore vascular dysfuntion. The aim of this project was to develop analytical methods suitable for the measurement of homocysteine and related metabolites in a routine clinical laboratory, and two methods have been established; i) for homocysteine, cysteine and methionine and ii) for asymmetric dimethylarginine, symmetric dimethylarginine (SDMA, a sterioisomer of ADMA), monomethylarginine (MMA) and arginine. A novel feature of the method for ADMA is that the use of unique daughter ions allows the determination of both ADMA and SDMA without the need to separate the isomers chromatographically. In addition, the synthesis and application of isotopically labelled SDMA, for use as an internal standard, is described for the first time. When the methods were applied to the analysis of routine clinical samples no association was detected between plasma total homocysteine and plasma ADMA concentrations. Measurements were also performed on samples from patients enrolled in a clinical trial investigating the progression of vascular dysfuntion, as measured by carotid-femoral pulse wave velocity (CF-PWV), in chronic kidney disease. Again no association could be found between plasma total homocysteine and plasma ADMA concentrations. In addition plasma total homocysteine was not a determinant of CF-PWV. These findings do not support the hypothesis that hyperhomocysteinaemia causes vascular disease by increasing ADMA concentrations.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • www.heartstats.org accessed 3/04/2010.
    • Ross R. (1999) Atherosclerosis - an inflammatory disease. New Engl J Med 340, 115-126.
    • Wang TJ, (2008) New cardiovascular risk factors exist, but are they clinically useful? Eur Heart J 29, 441-444.
    • Shishehbor MH, Oliveira LPJ, Lauer MS, Sprecher DL, Wolski K, Cho L, Hoogwerf BJ, Hazen, SL. (2008) Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 101, 1741-1746.
    • Yap S, Boers GHJ, Wilcken B, Wilcken DEL, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER. (2001) Vascular outcome in patients with 13 14 15 16 17 18 19 20 21 Ogino S, Wilson RB. (2003) Genotype and haplotype distributions of MTHFR 677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J Hum Genetics 48, 1-7.
    • 24 Wald DS, Law M, Morris JK. (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202-1208.
    • Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578- 1588.
    • Signorello MG, Segantin A, Passalacqua M, Leoncini G. Homocysteine decreases platelet NO level via protein kinase C activation. Nitic Oxide 20, 104-113.
    • Carlucci F, Tabucchi A. (2009) Capillary electrophoresis in the evaluation of aminothiols in body fluids. J Chrom B 877, 3347-3357.
    • Pfeiffer CM, Huff DL, Gunter EW. (1999) Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin Chem 45, 290-292.
    • Frantzen F, Faaren AL, Alfheim I, Nordhei AK. (1998) Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 44, 311-316.
    • McCann SJ, Gillingwater S, Keevil BG, Cooper DP, Morris MR. (2003) Measurement of total homocysteine in plasma and blood spots using liquid chromatography-tandem mass spectrometry: comparison with the plasma Abbot IMx method. Ann Clin Biochem 40, 161-165.
    • Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, Vallance P, McDonald N. (2001) Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 8, 679-683.
    • Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104, 2569-2575.
    • Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS. (2001) Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88, 1201-1203.
    • (2005) Asymmetric dimethylarginine and progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. J Am Soc Nephrol 16, 2456-2461.
    • Zhang W, Kaye DM. (2004) Simultaneous determination of arginine and seven metabolites in plasma by reversed-phase liquid chromatography with a timecontrolled ortho-phthaldialdehyde precolumn derivatisation. Anal Biochem 326, 87- 92.
    • Albsmeier J, Schwedhelm E, Schulze F, Kastner M, Böger RH. (2004) Determination of NG,NG-dimethyl-L-arginine, and endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. J Chrom B 809, 59-65.
    • Bramwell JC, Hill AV. (1922) The velocity of the pulse wave in man. Proc Soc Lond (Biol) 93, 298-306.
    • Laurent S, Cockcroft J, van Bortel J, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H on behalf of the European Network for non-invasive investigation of large arteries. (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27, 2588-2605.
    • Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D. (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans.
    • Circulation 109, 172-177.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article